- Home
- MRCC vs ACRS Comparison
MRCC vs ACRS Comparison
Compare MRCC & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRCC
- ACRS
- Stock Information
- Founded
- MRCC 2011
- ACRS 2012
- Country
- MRCC United States
- ACRS United States
- Employees
- MRCC N/A
- ACRS N/A
- Industry
- MRCC Investment Managers
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- MRCC Finance
- ACRS Health Care
- Exchange
- MRCC Nasdaq
- ACRS Nasdaq
- Market Cap
- MRCC 176.4M
- ACRS 127.6M
- IPO Year
- MRCC 2012
- ACRS 2015
- Fundamental
- Price
- MRCC $7.28
- ACRS $1.34
- Analyst Decision
- MRCC Hold
- ACRS Strong Buy
- Analyst Count
- MRCC 1
- ACRS 7
- Target Price
- MRCC $8.00
- ACRS $11.67
- AVG Volume (30 Days)
- MRCC 81.3K
- ACRS 927.6K
- Earning Date
- MRCC 05-07-2025
- ACRS 05-06-2025
- Dividend Yield
- MRCC 13.89%
- ACRS N/A
- EPS Growth
- MRCC 2515.72
- ACRS N/A
- EPS
- MRCC 0.45
- ACRS N/A
- Revenue
- MRCC $60,527,000.00
- ACRS $18,720,000.00
- Revenue This Year
- MRCC N/A
- ACRS N/A
- Revenue Next Year
- MRCC N/A
- ACRS $425.96
- P/E Ratio
- MRCC $16.28
- ACRS N/A
- Revenue Growth
- MRCC N/A
- ACRS N/A
- 52 Week Low
- MRCC $6.55
- ACRS $0.95
- 52 Week High
- MRCC $8.85
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- MRCC 47.14
- ACRS 47.87
- Support Level
- MRCC $6.99
- ACRS $1.10
- Resistance Level
- MRCC $7.39
- ACRS $1.23
- Average True Range (ATR)
- MRCC 0.28
- ACRS 0.11
- MACD
- MRCC 0.06
- ACRS 0.03
- Stochastic Oscillator
- MRCC 86.29
- ACRS 78.38
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.